Arkansas' "shot heard round the pharmacy world": Preventing pharmacy benefit managers from owning pharmacies raises an interesting question for the field.

This designation is significant because there are no FDA-approved treatments for transplant recipients with or preventing antibody-mediated rejection (AMR).

Pharmacy deserts challenge access to essential medications, but innovative solutions like telepharmacy and mobile units empower pharmacists to bridge the gap.

Patients with inflammatory rheumatic diseases may have a protective effect against serious COVID-19 outcomes once they receive a pneumococcal vaccination.

Laura R. Bobolts, PharmD, BCOP, shares actionable strategies for oncology pharmacists to navigate biosimilar and 505(b)(2) drug implementation, manage payer and formulary complexities, and optimize cost-effective care delivery across oncology service lines.

FDA fast-tracks TRE-515 for advanced prostate cancer, combining it with radiation therapy to enhance treatment outcomes and patient care.

Previously indicated to reduce the risk of end-stage kidney disease, cardiovascular death, and hospitalization for heart failure (HF) in chronic kidney disease, finerenone is now approved for patients with HF directly, offering a new treatment option.

Pharmacy-based clinical services demonstrate both public health impact and financial sustainability.

Innovative pharmacist-led care models—from tech-enabled Afib screenings and HPV immunizations to Medicare-supported diabetes prevention—demonstrate how pharmacies are redefining their role in team-based clinical care.

CBD use can elevate liver enzymes in 5% to 6% of adults, highlighting the need for monitoring and safe usage practices.

Dalpiciclib combined with endocrine therapy significantly enhances progression-free survival in HR+/HER2– breast cancer, as shown in the DAWNA-A trial.

States have expanded access to over-the-counter ivermectin, raising concerns among health experts about safety, misinformation, and self-medication risks.

Complete response letters, which indicate reasons why a drug could not be approved in its current form, offer insightful information to drug developers on the inner mechanisms of the FDA’s approval process.

A maternal pro-inflammatory diet during pregnancy raises the risk of offspring developing type 1 diabetes, highlighting the impact of nutrition on early health.

Annie Eisenbeis, PharmD, MBA, showcased how Missouri’s Pharmacy Vaccine Gap Closure Program is transforming pharmacy-based immunization services through scalable workflows, team training, and a redefined role for pharmacy technicians as community health workers.

Lara Zakaria, PharmD, introduced the topic of pharmaconutrition, urging pharmacists to integrate food, lifestyle, and gut health into patient care through evidence-based, practical interventions.

Lumatperone showed a 63% reduction in relapse risk for patients with schizophrenia, promising improved patient stability and care.

Gustavo Alva, MD, a board-certified psychiatrist, discusses the importance of mental health awareness among pharmacists and patients.

By closing the gap on patients recommended lipid-lowering therapies who do not receive them, researchers say that thousands of cardiovascular events could be prevented and billions of dollars would be saved.

mRNA-1273, marketed as Spikevax by Moderna, is now fully approved for individuals aged 6 months through 64 years with high-risk features for severe COVID-19.

Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, FAPO, discusses how oncology pharmacists can lead value-based care efforts under the Enhanced Oncology Model (EOM) by improving care coordination, managing costs, aligning with performance metrics, and leveraging clinical data systems to enhance patient outcomes.

Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, FAPO, discusses the value of the 2025 ATOPP Summit in advancing oncology pharmacy through collaboration, innovation, and actionable strategies aligned with evolving value-based care models.

Obesity and high-fat diets enhance the aggressiveness of triple-negative breast cancer through exosome-mediated mechanisms, revealing new therapeutic targets.

New research highlights the lower infection risk with zanubrutinib compared with venetoclax in CLL/SLL treatment, offering safer options for patients.